Scarica l'app Stockscreener
19.86
3.84%
0.735
Pre-mercato:
19.55
-0.31
-1.56%
Precedente Chiudi:
$19.12
Aprire:
$19.13
Volume 24 ore:
524.94K
Relative Volume:
3.18
Capitalizzazione di mercato:
$502.44M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.73%
1M Prestazione:
+33.20%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$19.13
$20.72
Intervallo di 1 settimana:
$18.21
$22.93
Portata 52W:
$13.36
$23.15
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Nome
Lb Pharmaceuticals Inc
Settore
Industria
Telefono
917-450-6581
Indirizzo
575 MADISON AVENUE, NEW YORK
Confronta LBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
19.86 | 483.85M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Iniziato | Leerink Partners | Outperform |
| 2025-10-06 | Iniziato | Piper Sandler | Overweight |
| 2025-10-06 | Iniziato | Stifel | Buy |
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6%What's Next? - MarketBeat
LB Pharmaceuticals added to Russell 2000 and 3000 Indexes - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Inc (NASDAQ:LBRX) Expands Mental Health Pipeline - Kalkine Media
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat
LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com South Africa
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com India
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
LB Pharmaceuticals names Kaya Pai Panandiker as CCO - The Pharma Letter
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer By Investing.com - Investing.com South Africa
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - The Manila Times
LB Pharmaceuticals, Inc Announces Appointment of Kaya Pai Panandiker as Chief Commercial Officer - MarketScreener
LB Pharmaceuticals - Nasdaq
LB Pharmaceuticals Reports Strong Q3 and Strategic Progress - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot - theheraldreview.com
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference - The Manila Times
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 - Investing.com Nigeria
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 By Investing.com - Investing.com South Africa
LBRX: IPO raised $327.8M; LB-102 advances with strong data; Q3 net loss narrows to $3.6M - TradingView
Lb Pharmaceuticals Inc Azioni (LBRX) Dati Finanziari
Non sono disponibili dati finanziari per Lb Pharmaceuticals Inc (LBRX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):